Local Control and Toxicity Outcomes After Stereotactic Body Radiation Therapy for Metastatic Osteosarcoma in Pediatric Patients
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Sohil Reddy und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University College of Medicine, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Osteosarcoma, Radiosurgery, Bone Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Pediatric osteosarcoma is an aggressive bone malignancy that presents significant challenges due to high rates of metastatic disease and relapse. It is often treated with palliative radiotherapy for symptom control, but achieving definitive local control (LC) with radiotherapy alone is challenging given its radioresistance. LC may be potentially improved by utilizing stereotactic body radiation therapy (SBRT) to deliver high biologically equivalent doses (BED).
Methods
This study evaluated the LC outcomes of pediatric patients with osteosarcoma and unresectable metastatic disease who were treated with SBRT. Progression‐free survival (PFS), overall survival (OS), and toxicities were assessed as secondary endpoints.
Results
The study included seven patients who received 34 courses of SBRT. The median age at diagnosis was 13.1 and 17.1 years at first SBRT. The common sites for SBRT were extraspinal osseous metastases (56%), pulmonary/mediastinal (29%), and spine (9%). At a median follow‐up of 6 months on a per‐lesion analysis, LC was achieved in 88% of lesions, with four lesions failing locally. All four local failures were found in patients receiving a BED ≤48 Gy. The median distant PFS was 2.4 months. Toxicities were present in four patients, all of which resolved with supportive treatment.
Conclusions
Our study demonstrated that SBRT is safe and effective at achieving LC in pediatric patients with unresectable metastatic osteosarcoma, though distant progression can limit survival outcomes. Further studies evaluating SBRT in combination with other therapies are needed to address distant progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Ohio State University College of Medicine, Columbus, Ohio, USA.
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
- Translational Therapeutics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
- Division of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children's, Columbus, Ohio, USA.
- Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio, USA.
ORCID-Profile: Jennifer H Aldrink, Bhuvana Setty, Joshua Palmer
Zitieren
APA
Reddy, S., Upadhyay, R., Klamer, B., Singh, R., Konieczkowski, D., Cripe, T., Yeager, N. D., Roberts, R. D., Aldrink, J. H., Setty, B., Scharschmidt, T., Palmer, J., & Baliga, S. (2025). Local Control and Toxicity Outcomes After Stereotactic Body Radiation Therapy for Metastatic Osteosarcoma in Pediatric Patients. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31834
Vancouver
Reddy S, Upadhyay R, Klamer B, Singh R, Konieczkowski D, Cripe T, et al. Local Control and Toxicity Outcomes After Stereotactic Body Radiation Therapy for Metastatic Osteosarcoma in Pediatric Patients. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31834
BibTeX
@article{Reddy2025,
author = {Reddy, Sohil and Upadhyay, Rituraj and Klamer, Brett and Singh, Raj and Konieczkowski, David and Cripe, Timothy and Yeager, Nicholas D and Roberts, Ryan D and Aldrink, Jennifer H and Setty, Bhuvana and Scharschmidt, Thomas and Palmer, Joshua and Baliga, Sujith},
title = {Local Control and Toxicity Outcomes After Stereotactic Body Radiation Therapy for Metastatic Osteosarcoma in Pediatric Patients},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31834}
}
EUVIMED